João Nuno Moreira

envie a um amigo share this

GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure

GMP-grade nanoparticle targeted to nucleolin downregulates tumor molecular signature, blocking growth and invasion, at low systemic exposure

Current challenges and emerging opportunities of CAR-T cell therapies

During the past few years, the establishment of immunotherapy (e.i. stimulation of the immune system to recognize and kill malignant cells) as a reliable therapeutic option to tackle cancer, has shifted the paradigm of cancer treatment. Among the different classes of cancer immunotherapies, including checkpoint inhibitor monoclonal antibodies (2018 Nobel Prize Physiology or Medicine), adoptive T cell therapies (ACTs), harboring CAR-T cells, are emerging as a revolutionary strategy to eliminate tumors.

As células CAR-T no combate ao cancro - desafios atuais e oportunidades futuras

O estabelecimento da imunoterapia - estimulação do sistema imunitário para que este reconheça e destrua as células tumorais - como uma abordagem terapêutica eficaz no combate ao cancro, é, indubitavelmente, um dos maiores marcos no tratamento das doenças oncológicas dos últimos anos.

Nucleolin expression improved intracellular drug delivery in glioblastoma cells

One of the major challenges in Glioblastoma (GBM) therapy relates with the existence of glioma stem-like cells (GSCs), known to be chemo- and radio-resistant. In our work, nucleolin overexpression in GBM cells resulted in a higher association of liposomes targeting nucleolin. Moreover, nucleolin was suggested as a potential marker in GSCs, and in the corresponding non-stem GBM cells. Doxorubicin delivered by liposomes targeting nucleolin enabled a higher level of cytotoxicity.

A expressão de nucleolina permite a entrega intracelular de fármacos em células de glioblastoma

Um dos principais desafios da terapia do glioblastoma (GBM) está relacionado com a existência de células do tipo estaminal (GSC), conhecidas por serem quimio e radiorresistentes. No nosso trabalho, a sobre-expressão de nucleolina em células de GBM conduziu a uma maior associação dos lipossomas que têm com alvo a nucleolina. Além disso, a nucleolina foi sugerida como um potencial marcador em GSCs e nas células GBM não-estaminais correspondentes. A doxorrubicina administrada através dos lipossomas dirigidos à nucleolina permitiu um nível mais elevado de citotoxicidade.

Anticancer activity and antibody-dependent cell-mediated cytotoxicity of novel anti-nucleolin antibodies

Nucleolin arises as a relevant target for cancer therapy, as it is overexpressed at the surface of cancer and angiogenic endothelial cells thus enabling a dual cellular targeting strategy. Immunotherapeutic strategies, albeit of proven therapeutic relevance, have been scarcely explored against this target. Therefore, this work aimed at engineering an anti-nucleolin VHH-based antibody capable of triggering anticancer immune responses. Herein, anti-nucleolin VHHs have been generated upon grafting F3 peptide-derived nucleolin-binding sequences onto a VHH CDR1 or CDR3.

Novos anticorpos anti-nucleolina com atividade anticancerígena e citotoxicidade celular dependente de anticorpos

A nucleolina surge como um potencial alvo terapêutico para tumores, uma vez que se encontra sobre-expressa à superfície de células cancerígenas e células endoteliais angiogénicas, permitindo desta forma estratégias de direcionamento multicelular. Porém, este alvo tem sido pouco explorado no contexto de estratégias de imunoterapia, de comprovada relevância terapêutica.

Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model

Treatment and management of breast cancer imposes a heavy burden on the public health care. However, in spite of the considerable advancements in the treatment of this malignancy in the recent years, many patients continue to progress to metastatic disease and, for those with advanced breast cancer, palliative care is oftentimes the endpoint. The manifestation of metastases is predictive of poor clinical outcome, and prevails one of the most challenging issues faced by cancer treatment today.

Inoculated Cell Density as a Determinant Factor of the Growth Dynamics and Metastatic Efficiency of a Breast Cancer Murine Model

Treatment and management of breast cancer imposes a heavy burden on the public health care. However, in spite of the considerable advancements in the treatment of this malignancy in the recent years, many patients continue to progress to metastatic disease and, for those with advanced breast cancer, palliative care is oftentimes the endpoint. The manifestation of metastases is predictive of poor clinical outcome, and prevails one of the most challenging issues faced by cancer treatment today.